A Phase 2 interventional study of Ruxolitinib and Capecitabine in Breast Cancer, sponsored by Incyte Corporation. Terminated at 107 sites in 6 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-02-13.
Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Breast Neoplasms by Incyte Corporation — none open to participants now, 2 under way, none of them phase 3. Breast Neoplasms · Incyte Corporation.
Among the 10 studies in Breast Neoplasms by Incyte Corporation, this one is the 4th largest by enrollment, is the only one that started in 2014, is one of 2 in phase 2, and was the 4th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →None of the 10 studies in Breast Neoplasms by Incyte Corporation is open now. The open studies under Breast Neoplasms, anywhere →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 7
First in 2007; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 149 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 103 across the 10 interventional studies. Of the 8 that completed or were terminated, 4 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
Incyte Corporation is the lead sponsor of 288 studies on the registry; 34 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
2 of the studies in Breast Neoplasms by Incyte Corporation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05238922Incyte CorporationStudy of INCB123667 in Subjects With Advanced Solid Tumors | 2027-07-27 |
| NCT02955940Incyte CorporationAn Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies in Breast Neoplasms by Incyte Corporation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This was a randomized, double-blind, placebo-controlled phase 2 clinical trial comparing the overall survival of women with advanced or metastatic HER2-negative breast cancer who received treatment with capecitabine in combination with ruxolitinib versus those who received treatment with capecitabine alone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
An mGPS of 1 or 2 as defined below:
Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Ruxolitinib · Drug: Capecitabine
Drug: Capecitabine · Drug: Placebo
5 mg tablets to be administered by mouth Ruxolitinib 15 mg BID (starting dose)
Also known as: Jakafi ®, Jakavi ®
Capecitabine 2000 mg/m\^2 daily given as 1000 mg/m\^2 twice a day (BID) (starting dose) Day 1-14 of each 21 day cycle
5 mg matching placebo tablets to be administered by mouth
Overall Survival (OS)
Overall survival is reported here by the number of days from randomization to death until the data cutoff for the final analysis. The hazard ratio (80% CI) for ruxolitinib versus placebo was estimated using a Cox regression model stratified by hormone-receptor status.
Time frame: Randomization until death due to any cause up to 19 months or the data cutoff 08FEB2016.
Median Survival
Survival was assessed by the time to death or censoring up until 08Feb2016. Participants with no observed death were treated as right-censored at their last date known to be alive. The survival time was analyzed using the Kaplan-Meier method.
Time frame: Randomization until death due to any cause up to 19 months or the data cutoff 08FEB2016.
Percentage of Participants Achieving Overall Survival
Overall survival was assessed by the time to death or censoring up until 08Feb2016. Participants with no observed death were treated as right-censored at their last date known to be alive. The survival time was analyzed using the Kaplan-Meier method.
Time frame: Randomization until death due to any cause at month 3, 6, 9, 12 and 15 or the data cutoff 08FEB2016.
Progression-free Survival (PFS)
Progression-free survival was defined as the time from the randomization date to the earliest date of disease progression, as measured by investigator assessment of objective radiographic disease assessments per RECIST (v1.1), or death from any cause if earlier. Progression-free survival time distribution and median survival for each treatment group were analyzed using the Kaplan-Meier method.
Time frame: Randomization to disease progression, or death due to any cause if sooner up to 19 months or the data cutoff 08FEB2016.
Percentage of Participants Achieving Objective Response Rate
Objective response rate determined by radiographic disease assessments per RECIST (v1.1), by investigator assessment and was defined as the percentage of participants with Complete Response (CR) or Partial Response (PR) by Response Evaluation Criteria in Solid Tumours (RECIST) at any post baseline visit. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) for target lesions and assessed by computed tomography (CT) and/or magnetic resonance imaging (MRI) : Complete Response (CR), Disappearance of all target and non-target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions with no worsening of non-target lesions and no new lesions; Overall Response (OR) = CR + PR.
Time frame: Randomization through end of study up to 19 months or the data cutoff 08FEB2016.
Duration of Response (DOR)
The DOR was defined as the difference (in number of months) between the end of response and the start of response for participants who had at least 1 response measurement. The start of a response was the first visit where the participant achieved a partial response or better based on RECIST (v1.1) criteria. The end of response was the earlier of death or progressive disease based on RECIST (v1.1) criteria. The date of progressive disease was the date on which progression was first recorded. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) for target lesions and assessed by computed tomography (CT) and/or magnetic resonance imaging (MRI) : Complete Response (CR), Disappearance of all target and non-target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions with no worsening of non-target lesions and no new lesions; Overall Response (OR) = CR + PR.
Time frame: Randomization through end of study up to 19 months or the data cutoff 08FEB2016.
Percentage of Participants Achieving Clinical Benefit Rate
Clinical benefit rate was defined as a complete response, partial response, or stable disease, determined by investigator assessment of objective radiographic disease assessments per RECIST (v1.1) that lasted for ≥ 6 months. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) for target lesions and assessed by computed tomography (CT) and/or magnetic resonance imaging (MRI) : Complete Response (CR), Disappearance of all target and non-target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions with no worsening of non-target lesions and no new lesions; Overall Response (OR) = CR + PR.
Time frame: Randomization through end of study up to 19 months or the data cutoff 08FEB2016.
This study was conducted at 72 study centers (65 in the United States and 7 in the European Union \[3 in the United Kingdom, 3 in Spain, and 1 in Portugal\]).
| Milestone | Treatment A - Capecitabine and Ruxolitinib | Treatment B - Capecitabine and Placebo |
|---|---|---|
| Started | 76 | 73 |
| Completed | 16 | 5 |
| Not completed | 60 | 68 |
| Withdrew: Death | 5 | 1 |
| Withdrew: Adverse event | 3 | 9 |
| Withdrew: Participant decision | 4 | 4 |
| Withdrew: Disease progression | 41 | 45 |
| Withdrew: Noncompliance with study treatment | 0 | 2 |
| Withdrew: Physician decision | 2 | 3 |
| Withdrew: Other unspecified | 5 | 4 |
Overall survival is reported here by the number of days from randomization to death until the data cutoff for the final analysis. The hazard ratio (80% CI) for ruxolitinib versus placebo was estimated using a Cox regression model stratified by hormone-receptor status.
| Participants | Treatment A - Capecitabine and Ruxolitinib | Treatment B - Capecitabine and Placebo |
|---|---|---|
| Death events | 39 | 38 |
| Censored events | 37 | 35 |
Survival was assessed by the time to death or censoring up until 08Feb2016. Participants with no observed death were treated as right-censored at their last date known to be alive. The survival time was analyzed using the Kaplan-Meier method.
| months | Treatment A - Capecitabine and Ruxolitinib | Treatment B - Capecitabine and Placebo |
|---|---|---|
| Median Survival | 11.2 (7.5 to 12.7) | 10.9 (6.0 to 13.1) |
Progression-free survival was defined as the time from the randomization date to the earliest date of disease progression, as measured by investigator assessment of objective radiographic disease assessments per RECIST (v1.1), or death from any cause if earlier. Progression-free survival time distribution and median survival for each treatment group were analyzed using the Kaplan-Meier method.
| months | Treatment A - Capecitabine and Ruxolitinib | Treatment B - Capecitabine and Placebo |
|---|---|---|
| Progression-free Survival (PFS) | 4.5 (2.3 to 6.1) | 2.5 (2.1 to 4.1) |
Objective response rate determined by radiographic disease assessments per RECIST (v1.1), by investigator assessment and was defined as the percentage of participants with Complete Response (CR) or Partial Response (PR) by Response Evaluation Criteria in Solid Tumours (RECIST) at any post baseline visit. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) for target lesions and assessed by computed tomography (CT) and/or magnetic resonance imaging (MRI) : Complete Response (CR), Disappearance of all target and non-target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions with no worsening of non-target lesions and no new lesions; Overall Response (OR) = CR + PR.
| percentage of participants | Treatment A - Capecitabine and Ruxolitinib | Treatment B - Capecitabine and Placebo |
|---|---|---|
| Complete Response rate | 0.0 | 0.0 |
| Partial Response rate | 28.9 | 13.7 |
The DOR was defined as the difference (in number of months) between the end of response and the start of response for participants who had at least 1 response measurement. The start of a response was the first visit where the participant achieved a partial response or better based on RECIST (v1.1) criteria. The end of response was the earlier of death or progressive disease based on RECIST (v1.1) criteria. The date of progressive disease was the date on which progression was first recorded. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) for target lesions and assessed by computed tomography (CT) and/or magnetic resonance imaging (MRI) : Complete Response (CR), Disappearance of all target and non-target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions with no worsening of non-target lesions and no new lesions; Overall Response (OR) = CR + PR.
| months | Treatment A - Capecitabine and Ruxolitinib | Treatment B - Capecitabine and Placebo |
|---|---|---|
| Duration of Response (DOR) | 4.2 (3.5 to 4.6) | 4.4 (3.8 to 6.4) |
Clinical benefit rate was defined as a complete response, partial response, or stable disease, determined by investigator assessment of objective radiographic disease assessments per RECIST (v1.1) that lasted for ≥ 6 months. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) for target lesions and assessed by computed tomography (CT) and/or magnetic resonance imaging (MRI) : Complete Response (CR), Disappearance of all target and non-target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions with no worsening of non-target lesions and no new lesions; Overall Response (OR) = CR + PR.
| percentage of participants | Treatment A - Capecitabine and Ruxolitinib | Treatment B - Capecitabine and Placebo |
|---|---|---|
| Percentage of Participants Achieving Clinical Benefit Rate | 13.2 | 6.8 |
Overall survival was assessed by the time to death or censoring up until 08Feb2016. Participants with no observed death were treated as right-censored at their last date known to be alive. The survival time was analyzed using the Kaplan-Meier method.
| percentage of participants | Treatment A - Capecitabine and Ruxolitinib | Treatment B - Capecitabine and Placebo |
|---|---|---|
| Month 3 Survival Rate | 0.855 (0.753 to 0.917) | 0.750 (0.633 to 0.835) |
| Month 6 Survival Rate | 0.674 (0.554 to 0.769) | 0.635 (0.511 to 0.735) |
| Month 9 Survival Rate | 0.537 (0.404 to 0.652) | 0.546 (0.417 to 0.657) |
| Month 12 Survival Rate | 0.435 (0.289 to 0.573) | 0.427 (0.286 to 0.561) |
| Month 15 Survival Rate | 0.319 (0.174 to 0.475) | 0.294 (0.148 to 0.456) |
Collected over Participants received study treatment in continuous 21-day cycles until they met withdrawal criteria up to 19 months or the data cutoff 08FEB2016. The cutoff date of 08Feb2016 was chosen based on the date that the sponsor became aware that the seventieth death had occurred in the randomized population.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment A - Capecitabine and Ruxolitinib | — | 28/71 (39.4%) | 69/71 (97.2%) |
| Treatment B - Capecitabine and Placebo | — | 29/71 (40.8%) | 69/71 (97.2%) |
| Event | Treatment A - Capecitabine and Ruxolitinib | Treatment B - Capecitabine and Placebo |
|---|---|---|
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 3/71 | 6/71 |
| NauseaGastrointestinal disorders | 5/71 | 1/71 |
| VomitingGastrointestinal disorders | 4/71 | 4/71 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/71 | 4/71 |
| PneumoniaInfections and infestations | 3/71 | 1/71 |
| DehydrationMetabolism and nutrition disorders | 3/71 | 1/71 |
| Deep vein thrombosisVascular disorders | 0/71 | 3/71 |
| NeutropeniaBlood and lymphatic system disorders | 2/71 | 0/71 |
| Abdominal painGastrointestinal disorders | 2/71 | 1/71 |
| AscitesGastrointestinal disorders | 0/71 | 2/71 |
| Event | Treatment A - Capecitabine and Ruxolitinib | Treatment B - Capecitabine and Placebo |
|---|---|---|
| FatigueGeneral disorders | 40/71 | 31/71 |
| NauseaGastrointestinal disorders | 39/71 | 35/71 |
| AnaemiaBlood and lymphatic system disorders | 35/71 | 18/71 |
| DiarrhoeaGastrointestinal disorders | 33/71 | 19/71 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 33/71 | 27/71 |
| VomitingGastrointestinal disorders | 26/71 | 19/71 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 22/71 | 20/71 |
| Decreased appetiteMetabolism and nutrition disorders | 21/71 | 19/71 |
| StomatitisGastrointestinal disorders | 19/71 | 12/71 |
| ConstipationGastrointestinal disorders | 18/71 | 17/71 |
The Intent-to-Treat (ITT) population consisted of all participants randomized to the study.
| Age, Continuous(years) | Treatment A - Capecitabine and Ruxolitinib | Treatment B - Capecitabine and Placebo | Total |
|---|---|---|---|
| Mean | 54.3 ± 11.00 | 55.0 ± 12.75 | 54.6 ± 11.85 |
| Sex: Female, Male(Participants) | Treatment A - Capecitabine and Ruxolitinib | Treatment B - Capecitabine and Placebo | Total |
|---|---|---|---|
| Female | 76 | 73 | 149 |
| Male | 0 | 0 | 0 |
Showing the first 100 of 107 sites across 6 countries. Choose a country and city above to see the rest.
Ran from May 2014 to primary completion in Feb 2016, 21 months.
Results were first posted in Jul 2017, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ruxolitinib